These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 16328101)

  • 1. Estimation of AUC from 0 to Infinity in Serial Sacrifice Designs.
    Wolfsegger MJ; Jaki T
    J Pharmacokinet Pharmacodyn; 2005 Dec; 32(5-6):757-66. PubMed ID: 16328101
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Establishing bioequivalence in serial sacrifice designs.
    Wolfsegger MJ
    J Pharmacokinet Pharmacodyn; 2007 Feb; 34(1):103-13. PubMed ID: 17053981
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Establishing bioequivalence in complete and incomplete data designs using AUCs.
    Jaki T; Wolfsegger MJ; Lawo JP
    J Biopharm Stat; 2010 Jul; 20(4):803-20. PubMed ID: 20496207
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A method for estimating and testing area under the curve in serial sacrifice, batch, and complete data designs.
    Holder DJ; Hsuan F; Dixit R; Soper K
    J Biopharm Stat; 1999 Aug; 9(3):451-64. PubMed ID: 10473031
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Non-compartmental estimation of pharmacokinetic parameters in serial sampling designs.
    Wolfsegger MJ; Jaki T
    J Pharmacokinet Pharmacodyn; 2009 Oct; 36(5):479-94. PubMed ID: 19847629
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Confidence intervals for ratios of AUCs in the case of serial sampling: a comparison of seven methods.
    Jaki T; Wolfsegger MJ; Ploner M
    Pharm Stat; 2009; 8(1):12-24. PubMed ID: 18407562
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design and inference for 3-stage bioequivalence testing with serial sampling data.
    Yan F; Zhu H; Liu J; Jiang L; Huang X
    Pharm Stat; 2018 Sep; 17(5):458-476. PubMed ID: 29726096
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bayesian approach to estimate AUC, partition coefficient and drug targeting index for studies with serial sacrifice design.
    Wang T; Baron K; Zhong W; Brundage R; Elmquist W
    Pharm Res; 2014 Mar; 31(3):649-59. PubMed ID: 24092052
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Estimation of confidence intervals for area under the curve from destructively obtained pharmacokinetic data.
    Gagnon RC; Peterson JJ
    J Pharmacokinet Biopharm; 1998 Feb; 26(1):87-102. PubMed ID: 9773394
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population pharmacokinetic measures, their estimation and selection of sampling times.
    Fedorov V; Leonov S
    J Biopharm Stat; 2007; 17(5):919-41. PubMed ID: 17885874
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Strategies to assess systemic exposure of chemicals in subchronic/chronic diet and drinking water studies.
    Saghir SA; Mendrala AL; Bartels MJ; Day SJ; Hansen SC; Sushynski JM; Bus JS
    Toxicol Appl Pharmacol; 2006 Mar; 211(3):245-60. PubMed ID: 16040073
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improved pharmacokinetic and bioavailability support of drug discovery using serial blood sampling in mice.
    Peng SX; Rockafellow BA; Skedzielewski TM; Huebert ND; Hageman W
    J Pharm Sci; 2009 May; 98(5):1877-84. PubMed ID: 18803263
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Some considerations on the design of population pharmacokinetic studies.
    Duffull S; Waterhouse T; Eccleston J
    J Pharmacokinet Pharmacodyn; 2005 Aug; 32(3-4):441-57. PubMed ID: 16284917
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Utility of capillary microsampling for rat pharmacokinetic studies: Comparison of tail-vein bleed to jugular vein cannula sampling.
    Korfmacher W; Luo Y; Ho S; Sun W; Shen L; Wang J; Wu Z; Guo Y; Snow G; O'Shea T
    J Pharmacol Toxicol Methods; 2015; 76():7-14. PubMed ID: 26164093
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bioequivalence study of generic tablet formulations containing ethinylestradiol and chlormadinone acetate in healthy female volunteers.
    Bonn M; Eydeler U; Barkworth M; Rovati LC
    Arzneimittelforschung; 2009; 59(12):651-8. PubMed ID: 20108652
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bioequivalence of two tablet formulations of capecitabine and exploration of age, gender, body surface area, and creatinine clearance as factors influencing systemic exposure in cancer patients.
    Cassidy J; Twelves C; Cameron D; Steward W; O'Byrne K; Jodrell D; Banken L; Goggin T; Jones D; Roos B; Bush E; Weidekamm E; Reigner B
    Cancer Chemother Pharmacol; 1999; 44(6):453-60. PubMed ID: 10550565
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The application of sample pooling methods for determining AUC, AUMC and mean residence times in pharmacokinetic studies.
    Cheung BW; Cartier LL; Russlie HQ; Sawchuk RJ
    Fundam Clin Pharmacol; 2005 Jun; 19(3):347-54. PubMed ID: 15910659
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Application of Hill's equation for estimating area under the concentration-time curve (AUC) and use of time to AUC 90% for expressing kinetics of drug disposition.
    Cheng HC
    J Pharmacol Toxicol Methods; 2009; 60(3):296-300. PubMed ID: 19439184
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics and bioequivalence evaluation of 2 levosulpiride preparations after a single oral dose in healthy male Korean volunteers.
    Cho HY; Moon JD; Lee YB
    Int J Clin Pharmacol Ther; 2004 Mar; 42(3):174-80. PubMed ID: 15049438
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Application and validation of an advanced gastrointestinal in vitro model for the evaluation of drug product performance in pharmaceutical development.
    Barker R; Abrahamsson B; Kruusmägi M
    J Pharm Sci; 2014 Nov; 103(11):3704-3712. PubMed ID: 25223814
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.